CN114206344A - 包含前列腺素类似物的局部组合物 - Google Patents

包含前列腺素类似物的局部组合物 Download PDF

Info

Publication number
CN114206344A
CN114206344A CN202080055661.8A CN202080055661A CN114206344A CN 114206344 A CN114206344 A CN 114206344A CN 202080055661 A CN202080055661 A CN 202080055661A CN 114206344 A CN114206344 A CN 114206344A
Authority
CN
China
Prior art keywords
composition
use according
latanoprost
hair
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080055661.8A
Other languages
English (en)
Chinese (zh)
Inventor
F·勒舍尔
B·豪普特梅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Demalik Therapy
Original Assignee
Novaliq GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq GmbH filed Critical Novaliq GmbH
Publication of CN114206344A publication Critical patent/CN114206344A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080055661.8A 2019-08-09 2020-08-06 包含前列腺素类似物的局部组合物 Pending CN114206344A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19191035.5 2019-08-09
EP19191035 2019-08-09
PCT/EP2020/072211 WO2021028328A1 (en) 2019-08-09 2020-08-06 Topical composition comprising a prostaglandin analogue

Publications (1)

Publication Number Publication Date
CN114206344A true CN114206344A (zh) 2022-03-18

Family

ID=67587648

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080055661.8A Pending CN114206344A (zh) 2019-08-09 2020-08-06 包含前列腺素类似物的局部组合物

Country Status (8)

Country Link
US (2) US20220362382A1 (https=)
EP (1) EP4009952A1 (https=)
JP (2) JP2022543402A (https=)
KR (1) KR20220044739A (https=)
CN (1) CN114206344A (https=)
AU (2) AU2020330424A1 (https=)
CA (1) CA3144193A1 (https=)
WO (1) WO2021028328A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2714010T3 (en) 2011-05-25 2017-06-12 Novaliq Gmbh TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
EP4374851B1 (en) 2016-12-23 2026-04-15 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
SG11202007860XA (en) 2018-03-28 2020-09-29 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
KR20220058577A (ko) 2019-09-06 2022-05-09 노바리크 게엠베하 포도막염 치료를 위한 안과용 조성물
WO2025133899A1 (en) 2023-12-19 2025-06-26 Glenmark Specialty S.A. Topical composition comprising dutasteride and latanoprost for alopecia
WO2025149998A1 (en) * 2024-01-11 2025-07-17 Glenmark Specialty S.A. Topical composition comprising clascoterone and latanoprost for alopecia
WO2026013128A1 (en) * 2024-07-10 2026-01-15 Dermaliq Therapeutics, Inc. Treatment of androgenetic alopecia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1021179B1 (en) * 1997-02-04 2004-05-12 Murray A. Johnstone Method of enhancing hair growth
JP2005225817A (ja) * 2004-02-13 2005-08-25 Jiyugaoka Clinic 睫毛用育毛剤
DK2498783T3 (en) * 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
US9149484B2 (en) * 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
PL2547323T3 (pl) * 2010-03-17 2016-07-29 Novaliq Gmbh Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
JP6023181B2 (ja) * 2011-05-25 2016-11-09 ノバリック ゲーエムベーハー 爪に投与するための医薬組成物
WO2013106565A1 (en) 2012-01-10 2013-07-18 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists
EP2944324A1 (de) * 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
PT3442480T (pt) * 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
MX2020003534A (es) * 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.

Also Published As

Publication number Publication date
JP2022543402A (ja) 2022-10-12
AU2026202586A1 (en) 2026-04-23
US20260041773A1 (en) 2026-02-12
AU2020330424A1 (en) 2022-03-03
CA3144193A1 (en) 2021-02-18
JP2025160428A (ja) 2025-10-22
US20220362382A1 (en) 2022-11-17
EP4009952A1 (en) 2022-06-15
WO2021028328A1 (en) 2021-02-18
KR20220044739A (ko) 2022-04-11

Similar Documents

Publication Publication Date Title
CN114206344A (zh) 包含前列腺素类似物的局部组合物
RU2567792C2 (ru) Композиции и способы стимулирования роста волос
US20240189324A1 (en) High concentration formulation
JP6082158B2 (ja) ビマトプロストを含む局所用組成物及びそれを用いた育毛の刺激方法
US9149484B2 (en) Compositions and methods for stimulating hair growth
EP3886799B1 (en) Compositions for the treatment of hair loss
EP4487852A1 (en) Transdermal dosage form, for promoting local blood flow, of dual-acting pde5 inhibitor/organic nitrate ester
KR20260055529A (ko) 국소 조성물
AU2016427261A1 (en) Pharmaceutical compositions
CN114025768A (zh) 促进毛发生长的药品
WO2026013128A1 (en) Treatment of androgenetic alopecia
AU2024243786A1 (en) Clascoterone and minoxidil combination therapy for use in treating hair loss
WO2025069091A1 (en) Novel topical pharmaceutical composition for prevention and treatment of hair loss
JP2026513803A (ja) 脱毛の治療において使用するためのクラスコテロンとミノキシジルとの併用治療
WO2026057588A1 (en) Clascoterone and minoxidil combination therapy for use in treating hair loss
WO2025172818A1 (en) Pyrilutamide combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right

Effective date of registration: 20220729

Address after: Delaware

Applicant after: Demalik therapy

Address before: Heidelberg, Germany

Applicant before: NOVALIQ GmbH

TA01 Transfer of patent application right
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination